Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0NS9H
|
||||
| Former ID |
DNC006850
|
||||
| Drug Name |
2-methyl-6-(4-phenylpent-1-ynyl)pyridine
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Discovery agent | Investigative | [1] | ||
| Structure |
|
Download2D MOL |
|||
| Formula |
C17H17N
|
||||
| Canonical SMILES |
CC1=CC=CC(=N1)C#CCC(C)C2=CC=CC=C2
|
||||
| InChI |
1S/C17H17N/c1-14(16-10-4-3-5-11-16)8-6-12-17-13-7-9-15(2)18-17/h3-5,7,9-11,13-14H,8H2,1-2H3
|
||||
| InChIKey |
QVXDBDKPSMNGHQ-UHFFFAOYSA-N
|
||||
| PubChem Compound ID | |||||
| Target and Pathway | |||||
| Target(s) | Metabotropic glutamate receptor 5 | Target Info | Inhibitor | [1] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Long-term potentiation | |||||
| Retrograde endocannabinoid signaling | |||||
| Glutamatergic synapse | |||||
| Huntington's disease | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | ||||
| Metabotropic glutamate receptor group III pathway | |||||
| Metabotropic glutamate receptor group I pathway | |||||
| Endogenous cannabinoid signaling | |||||
| Reactome | G alpha (q) signalling events | ||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| GPCRs, Class C Metabotropic glutamate, pheromone | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Bioorg Med Chem Lett. 2006 Sep 15;16(18):4788-91. Epub 2006 Jul 11.Structure-activity relationships for the linker in a series of pyridinyl-alkynes that are antagonists of the metabotropic glutamatereceptor 5 (mGluR5). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.